---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-059545"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:42:22.154249+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Manuel C. Alves Aivado resigns from Rein Therapeutics board effective Feb 16

## Summary
- Manuel C. Alves Aivado, M.D., Ph.D., resigned as board member effective February 16, 2026.
- Resignation was not the result of any disagreement with the company's operations, policies, or practices.
- No replacement has been announced; board size and composition subsequent to departure not disclosed.

## SEC filing metadata
- accession: 0001193125-26-059545
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312526059545/0001193125-26-059545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312526059545/d31606d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-059545
- JSON: https://secwatch.observer/filing/0001193125-26-059545.json
- Plain text: https://secwatch.observer/filing/0001193125-26-059545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.